Subiaco Hospital delivers first dose of new immunotherapy for advanced lung cancer, offering hope to patients

St John of God Subiaco Hospital has administered its first bispecific T-cell engager (BiTE) therapy to a patient enrolled in a major international clinical trial for advanced lung cancer, marking an important step forward in access to next-generation cancer treatments.

29 Jan 2026

L-R: Clinical Trial and Data Management Officer, Kirsten Loffell; Oncologist, A/Prof Tim Clay; Nurse Practitioner, Kate Austin; and Research Operations Manager Dr Natalya Beer

The global Phase 3 ABBIL1TY NSCLC-06 Study, led onsite by Oncologist, Associate Professor Tim Clay, is evaluating whether this new form of immunotherapy can provide better and longer-lasting outcomes for people with metastatic non-small cell lung cancer compared with standard chemotherapy.

BiTE therapies are a rapidly emerging type of immunotherapy already used in some blood cancers. They work by helping the body’s immune system better recognise and attack cancer cells. While currently available in Australia for the treatment of certain blood cancers, BiTE therapies are expected to become an important treatment option for solid tumours, including lung cancer, in the coming years.

A/Prof Tim Clay said the commencement of this therapy signals meaningful progress and renewed hope for patients.

“This trial gives participants early access to some of the most advanced immunotherapy available worldwide,” he said.

"The promise of BiTE therapies lies in helping the immune system more effectively recognise and attack cancer cells, offering the potential for longer lasting responses in cancers that have traditionally been difficult to treat.

“We’re proud to offer suitable patients access to this treatment and to be at the forefront of this important work, which has the potential to change lives.”

St John of God CEO Tina Chinery added that lung cancer remains Australia’s deadliest cancer, with nearly 9,000 lives lost each year.

“That’s why advancing access to treatments like BiTE therapies through research is so vital,” she said.

“St John of God Subiaco Hospital is proud to be among the most active cancer research centres globally. Approximately 80 per cent of our hospital’s 105 active research and clinical trial projects are focused on improving outcomes for people living with cancer”.

About St John of God Subiaco Hospital:

St John of God Subiaco Hospital is a world-class private hospital offering the highest quality medical and surgical care in a warm and welcoming environment. Many of Perth’s leading specialist physicians and surgeons practice at the 600-bed hospital, allowing inpatients, outpatients and day patients to access a comprehensive range of services including cancer, surgical, cardiovascular and women’s health services.

Media contact

Kate Klopper
Marketing and Communications Manager
St John of God Subiaco Hospital
0448 345 332
[email protected]